Stephen Dale

Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Harry P. Erba, Amir T. Fathi, Ghayas C. Issa et al. · Blood · 2022 · 71 citations

Medicine, Pharmacology, Pharmacotherapy +13

Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma

Pierluigi Porcu, Stacie Hudgens, Pietro Quaglino et al. · Clinical Lymphoma Myeloma & Leukemia · 2020 · 34 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed <i>NPM1-</i>m or <i>KMT2A</i>-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007

Amer M. Zeidan, Eunice S. Wang, Ghayas C. Issa et al. · Blood · 2024 · 32 citations

Medicine, Hematology, Oncology +11

Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in <i>PIK3CA</i> - and <i>HRAS</i> -Dysregulated HNSCC via Convergent Inhibition of mTOR Activity

Alison Smith, Stacia Chan, Zhiyong Wang et al. · Cancer Research · 2023 · 31 citations · Full text

Medicine, Oncology, Pharmacology +16

Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory <i>NPM1</i>-m or <i>KMT2A</i>-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007

Amir T. Fathi, Ghayas C. Issa, Eunice S. Wang et al. · Blood · 2024 · 25 citations

Medicine, Oncology, Pharmacotherapy +10